Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)

NCT07729137 is registered in ClinicalTrials.gov with Emmecell as lead sponsor.

NCT NCT07729137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 2 Study of EO2002 in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD)
Lead sponsor
Emmecell
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
February 29, 2028
Enrollment
121 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

corneal edema, corneal endothelial cell loss, corneal endothelial decompensation, corneal endothelial disorder, corneal endothelial dystrophy 1, endothelial cell loss, corneal, endothelial corneal dystrophy, fuchs, fuchs dystrophy, fuchs' endothelial dystrophy, pseudophakic bullous keratopathy, pseudophakic bullous keratopathy (pbk)